| Revenue growth | 29% YoY in Q1FY27 |
|---|---|
| Margins | EBITDA margin at 31.8%; guiding >30% from FY27+ |
| Order book | Healthy order book and internal pipeline mentioned |
| Demand visibility | Strong visibility on CDMO and commercial API pipelines |
| Management confidence | High; visibility on late-stage projects and commercial API supplies |
Growth
Revenue grew 29% YoY; EBITDA increased 66% YoY to ₹644 Cr; Net Profit surged 126% YoY to ₹368 Cr.
Outlook
Management guiding >30% EBITDA margins from FY27+. Cumulative CAPEX >₹3,000 Cr planned over FY27-28 to drive long-term growth.
Risks
Potential macro-economic volatility, currency fluctuations, and regulatory trends in global pharmaceutical markets.
Last quarter's promises, checked
Delivered
- Guided ROCE ~17.7% → delivered 19% (= BEAT)
- Guided ARV revenue mix to stay below 1/3 → delivered 33% (= BEAT)
- Guided FY27 capex INR 1,500 Cr → delivered INR 2,000 Cr guidance (= BEAT)
Partly delivered
- Guided Asset Turnover target >1.0x → delivered "almost there" (= PARTIAL)
Investor Presentation filed with BSE, NSE: LAURUSLABS. Summary written with AI assistance from the document.
Laurus Labs Ltd: key numbers
- Share price
- ₹2,007.00
- Market cap
- ₹1,08,441 Cr
- Revenue (annual)
- ₹6,813 Cr
- Net profit (annual)
- ₹888.8 Cr
- P/E (TTM)
- 99.2×Sector 50.4×
- Promoter holding
- 27.47%-0.02% QoQ
- FII holding
- 28.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Laurus Labs Ltd
All →Laurus Labs Earnings Call Transcript: Key Takeaways
Laurus Labs delivered record quarterly revenue and EBITDA margins, driven by strong CDMO commercial supplies and recovery in the affordable medicine portfolio.
- Call
- Guides 50% growth
Laurus Labs Investor Presentation: Key Takeaways
Laurus Labs delivered a strong Q1 FY27 with ₹2,026 Cr revenue (up 29% YoY), driven by robust CDMO growth. EBITDA margins expanded to 31.8% due to favorable product mix and operational leverage.
Laurus Labs Q1 FY27 Results: Net Profit ₹362.1 Cr, Up 123.9% YoY
Laurus Labs Ltd reported revenue from operations of ₹2,026 Cr (+29.1% YoY) and net profit of ₹362.1 Cr (+123.9% YoY) for Q1 FY27.
- Key figure
- Net profit ₹362.1 Cr · +123.9% YoY
Laurus Labs Earnings Call: Key Takeaways
Laurus Labs delivered strong Q4 FY26 results with 23% annual revenue growth and significant EBITDA margin expansion to 26.8%, driven by a transforming CDMO business and generic portfolio ramp-up.
Laurus Labs Earnings Call: Key Takeaways
Laurus Labs delivered a robust 23% revenue growth in FY26, pivotally shifting its mix toward CDMO which now accounts for 30% of sales while maintaining ARV leadership.
Laurus Labs Earnings Call: Key Takeaways
Laurus Labs delivered record FY26 results with Revenue up 23% and Net Profit surging 148%, driven by a significant 36% jump in CDMO and improved operating leverage.